nach oben

NeuroMolecular Medicine

Erschienen in:

21.05.2016 | Review Paper

Targeting MicroRNAs Involved in the BDNF Signaling Impairment in Neurodegenerative Diseases

verfasst von: Hwa Jeong You, Jae Hyon Park, Helios Pareja-Galeano, Alejandro Lucia, Jae Il Shin

Erschienen in: NeuroMolecular Medicine | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Neurodegenerative diseases are becoming an ever-increasing problem in aging populations. Low levels of brain-derived neurotrophic factor (BDNF) have previously been associated with the pathogenesis of numerous neurodegenerative diseases. Recently, microRNAs (miRNAs) have been proposed as potential novel therapeutic targets for treating various diseases of the central nervous system (CNS), and interestingly, few studies have reported several miRNAs that downregulate the expression levels of BDNF. However, substantial challenges exist when attempting to translate these findings into practical anti-miRNA therapeutics, especially when the targets remain inside the CNS. Thus, in this review, we summarize the specific molecular mechanisms by which several miRNAs negatively modulate the expressions of BDNF, address the potential clinical difficulties that can be faced during the development of anti-miRNA-based therapeutics and propose strategies to overcome these challenges.

Aagaard, L., & Rossi, J. J. (2007). RNAi therapeutics: Principles, prospects and challenges. Advanced Drug Delivery Reviews, 59(2–3), 75–86. doi:10.1016/j.addr.2007.03.005.CrossRefPubMedPubMedCentral

Ahlskog, J. E. (2011). Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology, 77(3), 288–294. doi:10.1212/WNL.0b013e318225ab66.CrossRefPubMedPubMedCentral

Angelucci, F., Piermaria, J., Gelfo, F., Shofany, J., Tramontano, M., Fiore, M., et al. (2016). The effects of motor rehabilitation training on clinical symptoms and serum BDNF levels in Parkinson’s disease subjects. Canadian Journal of Physiology and Pharmacology. doi:10.1139/cjpp-2015-0322.PubMed

Autry, A. E., & Monteggia, L. M. (2012). Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacological Reviews, 64(2), 238–258. doi:10.1124/pr.111.005108.CrossRefPubMedPubMedCentral

Barnham, K. J., Masters, C. L., & Bush, A. I. (2004). Neurodegenerative diseases and oxidative stress. Nature Reviews Drug Discovery, 3(3), 205–214. doi:10.1038/nrd1330.CrossRefPubMed

Berchtold, N. C., Chinn, G., Chou, M., Kesslak, J. P., & Cotman, C. W. (2005). Exercise primes a molecular memory for brain-derived neurotrophic factor protein induction in the rat hippocampus. Neuroscience, 133(3), 853–861. doi:10.1016/j.neuroscience.2005.03.026.CrossRefPubMed

Berchtold, N. C., Kesslak, J. P., Pike, C. J., Adlard, P. A., & Cotman, C. W. (2001). Estrogen and exercise interact to regulate brain-derived neurotrophic factor mRNA and protein expression in the hippocampus. European Journal of Neuroscience, 14(12), 1992–2002.CrossRefPubMed

Bibel, M., & Barde, Y.-A. (2000). Neurotrophins: Key regulators of cell fate and cell shape in the vertebrate nervous system. Genes & Development, 14(23), 2919–2937.CrossRef

Bredy, T. W., Lin, Q., Wei, W., Baker-Andresen, D., & Mattick, J. S. (2011). MicroRNA regulation of neural plasticity and memory. Neurobiology of Learning and Memory, 96(1), 89–94. doi:10.1016/j.nlm.2011.04.004.CrossRefPubMed

Buchman, A. S., Yu, L., Boyle, P. A., Schneider, J. A., De Jager, P. L., & Bennett, D. A. (2016). Higher brain BDNF gene expression is associated with slower cognitive decline in older adults. Neurology, 86(8), 735–741. doi:10.1212/wnl.0000000000002387.CrossRefPubMed

Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. (2006). RNAi therapeutics: A potential new class of pharmaceutical drugs. Nature Chemical Biology, 2(12), 711–719. doi:10.1038/nchembio839.CrossRefPubMed

Cao, L., Lin, E. J., Cahill, M. C., Wang, C., Liu, X., & During, M. J. (2009). Molecular therapy of obesity and diabetes by a physiological autoregulatory approach. Nature Medicine, 15(4), 447–454. doi:10.1038/nm.1933.CrossRefPubMedPubMedCentral

Caputo, V., Sinibaldi, L., Fiorentino, A., Parisi, C., Catalanotto, C., Pasini, A., et al. (2011). Brain derived neurotrophic factor (BDNF) expression is regulated by microRNAs miR-26a and miR-26b allele-specific binding. PLoS One, 6(12), e28656.CrossRefPubMedPubMedCentral

Carthew, R. W., & Sontheimer, E. J. (2009). Origins and mechanisms of miRNAs and siRNAs. Cell, 136(4), 642–655.CrossRefPubMedPubMedCentral

Chen, Y., Zhu, X., Zhang, X., Liu, B., & Huang, L. (2010). Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Molecular Therapy, 18(9), 1650–1656. doi:10.1038/mt.2010.136.CrossRefPubMedPubMedCentral

Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., et al. (2008). Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. Journal of Alzheimer’s Disease, 14(1), 27–41.PubMed

Colbert, L. H., Visser, M., Simonsick, E. M., Tracy, R. P., Newman, A. B., Kritchevsky, S. B., et al. (2004). Physical activity, exercise, and inflammatory markers in older adults: Findings from the Health, Aging and Body Composition Study. Journal of the American Geriatrics Society, 52(7), 1098–1104. doi:10.1111/j.1532-5415.2004.52307.x.CrossRefPubMed

Cruickshank, T. M., Thompson, J. A., Dominguez, D. J., Reyes, A. P., Bynevelt, M., Georgiou-Karistianis, N., et al. (2015). The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington’s disease: An exploratory study. Brain and Behavior, 5(2), e00312. doi:10.1002/brb3.312.CrossRefPubMedPubMedCentral

Davis, S., Propp, S., Freier, S. M., Jones, L. E., Serra, M. J., Kinberger, G., et al. (2009). Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Research, 37(1), 70–77.CrossRefPubMed

de Fougerolles, A., Vornlocher, H. P., Maraganore, J., & Lieberman, J. (2007). Interfering with disease: A progress report on siRNA-based therapeutics. Nature Reviews Drug Discovery, 6(6), 443–453. doi:10.1038/nrd2310.CrossRefPubMed

Ding, Q., Vaynman, S., Akhavan, M., Ying, Z., & Gomez-Pinilla, F. (2006). Insulin-like growth factor I interfaces with brain-derived neurotrophic factor-mediated synaptic plasticity to modulate aspects of exercise-induced cognitive function. Neuroscience, 140(3), 823–833. doi:10.1016/j.neuroscience.2006.02.084.CrossRefPubMed

Diniz, B. S., & Teixeira, A. L. (2011). Brain-derived neurotrophic factor and Alzheimer’s disease: Physiopathology and beyond. Neuromolecular Medicine, 13(4), 217–222. doi:10.1007/s12017-011-8154-x.CrossRefPubMed

Ellis, T., Cavanaugh, J. T., Earhart, G. M., Ford, M. P., Foreman, K. B., Fredman, L., et al. (2011). Factors associated with exercise behavior in people with Parkinson disease. Physical Therapy, 91(12), 1838–1848. doi:10.2522/ptj.20100390.CrossRefPubMedPubMedCentral

Erickson, K. I., Miller, D. L., & Roecklein, K. A. (2012). The aging hippocampus: Interactions between exercise, depression, and BDNF. Neuroscientist, 18(1), 82–97. doi:10.1177/1073858410397054.CrossRefPubMed

Erickson, K. I., Voss, M. W., Prakash, R. S., Basak, C., Szabo, A., Chaddock, L., et al. (2011). Exercise training increases size of hippocampus and improves memory. Proceedings of the National Academy of Sciences USA, 108(7), 3017–3022. doi:10.1073/pnas.1015950108.CrossRef

Ferrer, I., Goutan, E., Marin, C., Rey, M. J., & Ribalta, T. (2000). Brain-derived neurotrophic factor in Huntington disease. Brain Research, 866(1–2), 257–261.CrossRefPubMed

Forero, D. A., van der Ven, K., Callaerts, P., & Del-Favero, J. (2010). miRNA genes and the brain: Implications for psychiatric disorders. Human Mutation, 31(11), 1195–1204. doi:10.1002/humu.21344.CrossRefPubMed

Fukuda, T., Itoh, M., Ichikawa, T., Washiyama, K., & Goto, Y. (2005). Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. Journal of Neuropathology and Experimental Neurology, 64(6), 537–544.CrossRefPubMed

Gao, J., Wang, W.-Y., Mao, Y.-W., Gräff, J., Guan, J.-S., Pan, L., et al. (2010). A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature, 466(7310), 1105–1109.CrossRefPubMedPubMedCentral

Garcia-Mesa, Y., Pareja-Galeano, H., Bonet-Costa, V., Revilla, S., Gomez-Cabrera, M. C., Gambini, J., et al. (2014). Physical exercise neuroprotects ovariectomized 3xTg-AD mice through BDNF mechanisms. Psychoneuroendocrinology, 45, 154–166. doi:10.1016/j.psyneuen.2014.03.021.CrossRefPubMed

Garzon, R., Marcucci, G., & Croce, C. M. (2010). Targeting microRNAs in cancer: Rationale, strategies and challenges. Nature Reviews Drug Discovery, 9(10), 775–789. doi:10.1038/nrd3179.CrossRefPubMedPubMedCentral

Georges, M., Coppieters, W., & Charlier, C. (2007). Polymorphic miRNA-mediated gene regulation: Contribution to phenotypic variation and disease. Current Opinion in Genetics & Development, 17(3), 166–176.CrossRef

Ghose, J., Sinha, M., Das, E., Jana, N. R., & Bhattacharyya, N. P. (2011). Regulation of miR-146a by RelA/NFkB and p53 in STHdh(Q111)/Hdh(Q111) cells, a cell model of Huntington’s disease. PLoS One, 6(8), e23837. doi:10.1371/journal.pone.0023837.CrossRefPubMedPubMedCentral

Gomez-Pinilla, F., Ying, Z., Roy, R. R., Molteni, R., & Edgerton, V. R. (2002). Voluntary exercise induces a BDNF-mediated mechanism that promotes neuroplasticity. Journal of Neurophysiology, 88(5), 2187–2195. doi:10.1152/jn.00152.2002.CrossRefPubMed

Guidi, M., Muinos-Gimeno, M., Kagerbauer, B., Marti, E., Estivill, X., & Espinosa-Parrilla, Y. (2010). Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells. BMC Molecular Biology, 11, 95. doi:10.1186/1471-2199-11-95.CrossRefPubMedPubMedCentral

Ha, M., & Kim, V. N. (2014). Regulation of microRNA biogenesis. Nature Reviews Molecular Cell Biology, 15(8), 509–524.CrossRefPubMed

Hass, C. J., Buckley, T. A., Pitsikoulis, C., & Barthelemy, E. J. (2012). Progressive resistance training improves gait initiation in individuals with Parkinson’s disease. Gait Posture, 35(4), 669–673. doi:10.1016/j.gaitpost.2011.12.022.CrossRefPubMed

Hendrickson, D. G., Hogan, D. J., McCullough, H. L., Myers, J. W., Herschlag, D., Ferrell, J. E., et al. (2009). Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA. PLoS Biology, 7(11), e1000238.CrossRefPubMedPubMedCentral

Herman, T., Giladi, N., & Hausdorff, J. M. (2009). Treadmill training for the treatment of gait disturbances in people with Parkinson’s disease: A mini-review. J Neural Transm (Vienna), 116(3), 307–318. doi:10.1007/s00702-008-0139-z.CrossRef

Hernandez, S. S., Sandreschi, P. F., da Silva, F. C., Arancibia, B. A., da Silva, R., Gutierres, P. J., et al. (2015). What are the benefits of exercise for Alzheimer’s disease? A systematic review of the past 10 years. Journal of Aging, Physical Activity, 23(4), 659–668. doi:10.1123/japa.2014-0180.CrossRef

Hutvágner, G., Simard, M. J., Mello, C. C., & Zamore, P. D. (2004). Sequence-specific inhibition of small RNA function. PLoS Biology, 2(4), e98.CrossRefPubMedPubMedCentral

Im, H.-I., Hollander, J. A., Bali, P., & Kenny, P. J. (2010). MeCP2 controls BDNF expression and cocaine intake through homeostatic interactions with microRNA-212. Nature Neuroscience, 13(9), 1120–1127.CrossRefPubMedPubMedCentral

Inukai, S., de Lencastre, A., Turner, M., & Slack, F. (2012). Novel microRNAs differentially expressed during aging in the mouse brain. PLoS One, 7(7), e40028. doi:10.1371/journal.pone.0040028.CrossRefPubMedPubMedCentral

Irmady, K., Jackman, K. A., Padow, V. A., Shahani, N., Martin, L. A., Cerchietti, L., et al. (2014). Mir-592 regulates the induction and cell death-promoting activity of p75NTR in neuronal ischemic injury. Journal of Neuroscience, 34(9), 3419–3428. doi:10.1523/jneurosci.1982-13.2014.CrossRefPubMedPubMedCentral

Jimenez-Mateos, E. M., Engel, T., Merino-Serrais, P., McKiernan, R. C., Tanaka, K., Mouri, G., et al. (2012). Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nature Medicine, 18(7), 1087–1094. doi:10.1038/nm.2834.CrossRefPubMedPubMedCentral

Johannessen, M., Delghandi, M. P., & Moens, U. (2004). What turns CREB on? Cellular Signalling, 16(11), 1211–1227. doi:10.1016/j.cellsig.2004.05.001.CrossRefPubMed

Jugloff, D. G., Jung, B. P., Purushotham, D., Logan, R., & Eubanks, J. H. (2005). Increased dendritic complexity and axonal length in cultured mouse cortical neurons overexpressing methyl-CpG-binding protein MeCP2. Neurobiology of Diseases, 19(1–2), 18–27. doi:10.1016/j.nbd.2004.11.002.CrossRef

Karege, F., Schwald, M., & Cisse, M. (2002). Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neuroscience Letters, 328(3), 261–264.CrossRefPubMed

Keifer, J., Zheng, Z., & Ambigapathy, G. (2015). A MicroRNA-BDNF negative feedback signaling loop in brain: Implications for Alzheimer’s disease. MicroRNA, 4(2), 101–108.CrossRefPubMed

Klein, M. E., Lioy, D. T., Ma, L., Impey, S., Mandel, G., & Goodman, R. H. (2007). Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nature Neuroscience, 10(12), 1513–1514.CrossRefPubMed

Kocerha, J., Kauppinen, S., & Wahlestedt, C. (2009). microRNAs in CNS disorders. Neuromolecular Medicine, 11(3), 162–172.CrossRefPubMed

Kolbeck, R., Bartke, I., Eberle, W., & Barde, Y. A. (1999). Brain-derived neurotrophic factor levels in the nervous system of wild-type and neurotrophin gene mutant mice. Journal of Neurochemistry, 72(5), 1930–1938.CrossRefPubMed

Konopka, W., Kiryk, A., Novak, M., Herwerth, M., Parkitna, J. R., Wawrzyniak, M., et al. (2010). MicroRNA loss enhances learning and memory in mice. The Journal of Neuroscience, 30(44), 14835–14842.CrossRefPubMed

Kosik, K. S., & Krichevsky, A. M. (2005). The elegance of the MicroRNAs: A neuronal perspective. Neuron, 47(6), 779–782. doi:10.1016/j.neuron.2005.08.019.CrossRefPubMed

Krol, J., Busskamp, V., Markiewicz, I., Stadler, M. B., Ribi, S., Richter, J., et al. (2010). Characterizing light-regulated retinal microRNAs reveals rapid turnover as a common property of neuronal microRNAs. Cell, 141(4), 618–631. doi:10.1016/j.cell.2010.03.039.CrossRefPubMed

Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., et al. (2005). Silencing of microRNAs in vivo with ‘antagomirs’. Nature, 438(7068), 685–689. doi:10.1038/nature04303.CrossRefPubMed

Lee, S. T., Chu, K., Jung, K. H., Kim, J. H., Huh, J. Y., Yoon, H., et al. (2012). miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Annals of Neurology, 72(2), 269–277.CrossRefPubMed

Lee, J., Fukumoto, H., Orne, J., Klucken, J., Raju, S., Vanderburg, C. R., et al. (2005). Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms. Experimental Neurology, 194(1), 91–96. doi:10.1016/j.expneurol.2005.01.026.CrossRefPubMed

Lee, R., Kermani, P., Teng, K. K., & Hempstead, B. L. (2001). Regulation of cell survival by secreted proneurotrophins. Science, 294(5548), 1945–1948. doi:10.1126/science.1065057.CrossRefPubMed

Liang, H., & Li, W.-H. (2007). MicroRNA regulation of human protein–protein interaction network. RNA, 13(9), 1402–1408.CrossRefPubMedPubMedCentral

Lima, L. O., Scianni, A., & Rodrigues-de-Paula, F. (2013). Progressive resistance exercise improves strength and physical performance in people with mild to moderate Parkinson’s disease: A systematic review. Journal of Physiotherapy, 59(1), 7–13. doi:10.1016/S1836-9553(13)70141-3.CrossRefPubMed

Lindvall, O., Kokaia, Z., Bengzon, J., Elmer, E., & Kokaia, M. (1994). Neurotrophins and brain insults. Trends in Neurosciences, 17(11), 490–496.CrossRefPubMed

Liu, D.-Y., Shen, X.-M., Yuan, F.-F., Guo, O.-Y., Zhong, Y., Chen, J.-G., et al. (2014). The physiology of BDNF and its relationship with ADHD. Molecular Neurobiology, 52(3), 1467–1476.CrossRefPubMed

Lu, B., Nagappan, G., Guan, X., Nathan, P. J., & Wren, P. (2013). BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nature Reviews Neuroscience, 14(6), 401–416.CrossRefPubMed

Lu, B., Pang, P. T., & Woo, N. H. (2005). The yin and yang of neurotrophin action. Nature Reviews Neuroscience, 6(8), 603–614.CrossRefPubMed

Lukiw, W. J. (2012). NF-small ka, CyrillicB-regulated micro RNAs (miRNAs) in primary human brain cells. Experimental Neurology, 235(2), 484–490. doi:10.1016/j.expneurol.2011.11.022.CrossRefPubMed

Maes, O. C., Chertkow, H. M., Wang, E., & Schipper, H. M. (2009). MicroRNA: Implications for Alzheimer disease and other human CNS disorders. Current Genomics, 10(3), 154.CrossRefPubMedPubMedCentral

Maisonpierre, P. C., Belluscio, L., Friedman, B., Alderson, R. F., Wiegand, S. J., Furth, M. E., et al. (1990). NT-3, BDNF, and NGF in the developing rat nervous system: Parallel as well as reciprocal patterns of expression. Neuron, 5(4), 501–509.CrossRefPubMed

Marti, E., Pantano, L., Banez-Coronel, M., Llorens, F., Minones-Moyano, E., Porta, S., et al. (2010). A myriad of miRNA variants in control and Huntington’s disease brain regions detected by massively parallel sequencing. Nucleic Acids Research, 38(20), 7219–7235. doi:10.1093/nar/gkq575.CrossRefPubMedPubMedCentral

Mellios, N., Huang, H.-S., Grigorenko, A., Rogaev, E., & Akbarian, S. (2008). A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex. Human Molecular Genetics, 17(19), 3030–3042.CrossRefPubMedPubMedCentral

Menzies, F. M., Fleming, A., & Rubinsztein, D. C. (2015). Compromised autophagy and neurodegenerative diseases. Nature Reviews Neuroscience, 16(6), 345–357. doi:10.1038/nrn3961.CrossRefPubMed

Miura, P., Amirouche, A., Clow, C., Belanger, G., & Jasmin, B. J. (2012). Brain-derived neurotrophic factor expression is repressed during myogenic differentiation by miR-206. Journal of Neurochemistry, 120(2), 230–238. doi:10.1111/j.1471-4159.2011.07583.x.CrossRefPubMed

Murer, M. G., Yan, Q., & Raisman-Vozari, R. (2001). Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease. Progress in Neurobiology, 63(1), 71–124.CrossRefPubMed

Nagahara, A. H., & Tuszynski, M. H. (2011). Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nature Reviews Drug Discovery, 10(3), 209–219.CrossRefPubMed

Narisawa-Saito, M., Wakabayashi, K., Tsuji, S., Takahashi, H., & Nawa, H. (1996). Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer’s disease. Neuroreport, 7(18), 2925–2928.CrossRefPubMed

Ninan, I. (2014). Synaptic regulation of affective behaviors; role of BDNF. Neuropharmacology, 76 Pt C, 684–695. doi:10.1016/j.neuropharm.2013.04.011.CrossRefPubMed

Pang, P. T., Teng, H. K., Zaitsev, E., Woo, N. T., Sakata, K., Zhen, S., et al. (2004). Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science, 306(5695), 487–491. doi:10.1126/science.1100135.CrossRefPubMed

Pareja-Galeano, H., Garatachea, N., & Lucia, A. (2015). Exercise as a polypill for chronic diseases. Progress in Molecular Biology and Translational Science, 135, 497–526. doi:10.1016/bs.pmbts.2015.07.019.CrossRefPubMed

Peedicayil, J. (2015). Epigenetic targets for the treatment of neurodegenerative diseases. Clinical Pharmacology and Therapeutics,. doi:10.1002/cpt.323.

Peng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. (2005). Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. Journal of Neurochemistry, 93(6), 1412–1421. doi:10.1111/j.1471-4159.2005.03135.x.CrossRefPubMed

Petersen, M., Bondensgaard, K., Wengel, J., & Jacobsen, J. P. (2002). Locked nucleic acid (LNA) recognition of RNA: NMR solution structures of LNA: RNA hybrids. Journal of the American Chemical Society, 124(21), 5974–5982.CrossRefPubMed

Petersen, M., & Wengel, J. (2003). LNA: A versatile tool for therapeutics and genomics. Trends in Biotechnology, 21(2), 74–81.CrossRefPubMed

Phillips, H. S., Hains, J. M., Armanini, M., Laramee, G. R., Johnson, S. A., & Winslow, J. W. (1991). BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron, 7(5), 695–702.CrossRefPubMed

Remenyi, J., Hunter, C., Cole, C., Ando, H., Impey, S., Monk, C., et al. (2010). Regulation of the miR-212/132 locus by MSK1 and CREB in response to neurotrophins. Biochemical Journal, 428, 281–291.CrossRefPubMed

Salta, E., & De Strooper, B. (2012). Non-coding RNAs with essential roles in neurodegenerative disorders. Lancet Neurology, 11(2), 189–200. doi:10.1016/S1474-4422(11)70286-1.CrossRefPubMed

Schratt, G. M., Tuebing, F., Nigh, E. A., Kane, C. G., Sabatini, M. E., Kiebler, M., et al. (2006). A brain-specific microRNA regulates dendritic spine development. Nature, 439(7074), 283–289.CrossRefPubMed

Sethi, P., & Lukiw, W. J. (2009). Micro-RNA abundance and stability in human brain: Specific alterations in Alzheimer’s disease temporal lobe neocortex. Neuroscience Letters, 459(2), 100–104.CrossRefPubMed

Sethupathy, P., Borel, C., Gagnebin, M., Grant, G. R., Deutsch, S., Elton, T. S., et al. (2007). Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: A mechanism for functional single-nucleotide polymorphisms related to phenotypes. The American Journal of Human Genetics, 81(2), 405–413.CrossRefPubMed

Sheinerman, K. S., Tsivinsky, V. G., Crawford, F., Mullan, M. J., Abdullah, L., & Umansky, S. R. (2012). Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging (Albany NY), 4(9), 590.CrossRef

Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., et al. (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women’s Health Initiative Memory Study—a randomized controlled trial. JAMA, 289(20), 2651–2662. doi:10.1001/jama.289.20.2651.CrossRefPubMed

Silva, A. J., Kogan, J. H., Frankland, P. W., & Kida, S. (1998). CREB and memory. The Annual Review of Neuroscience, 21, 127–148. doi:10.1146/annurev.neuro.21.1.127.CrossRefPubMed

Solum, D. T., & Handa, R. J. (2002). Estrogen regulates the development of brain-derived neurotrophic factor mRNA and protein in the rat hippocampus. Journal of Neuroscience, 22(7), 2650–2659.PubMed

Soto, C. (2003). Unfolding the role of protein misfolding in neurodegenerative diseases. Nature Reviews Neuroscience, 4(1), 49–60. doi:10.1038/nrn1007.CrossRefPubMed

Tapia-Arancibia, L., Rage, F., Givalois, L., & Arancibia, S. (2004). Physiology of BDNF: Focus on hypothalamic function. Frontiers in Neuroendocrinology, 25(2), 77–107.CrossRefPubMed

Teng, H. K., Teng, K. K., Lee, R., Wright, S., Tevar, S., Almeida, R. D., et al. (2005). ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. Journal of Neuroscience, 25(22), 5455–5463. doi:10.1523/JNEUROSCI.5123-04.2005.CrossRefPubMed

Underwood, C. K., & Coulson, E. J. (2008). The p75 neurotrophin receptor. International Journal of Biochemistry & Cell Biology, 40(9), 1664–1668. doi:10.1016/j.biocel.2007.06.010.CrossRef

Vorhies, J. S., & Nemunaitis, J. (2007). Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies. Expert Review of Anticancer Therapy, 7(3), 373–382. doi:10.1586/14737140.7.3.373.CrossRefPubMed

Wayman, G. A., Davare, M., Ando, H., Fortin, D., Varlamova, O., Cheng, H. Y., et al. (2008). An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP. Proceedings of the National Academy of Sciences of the USA, 105(26), 9093–9098. doi:10.1073/pnas.0803072105.CrossRefPubMedPubMedCentral

Widenfalk, J., Olson, L., & Thoren, P. (1999). Deprived of habitual running, rats downregulate BDNF and TrkB messages in the brain. Neuroscience Research, 34(3), 125–132.CrossRefPubMed

Wu, Y. W., Du, X., van den Buuse, M., & Hill, R. A. (2015). Analyzing the influence of BDNF heterozygosity on spatial memory response to 17beta-estradiol. Translational Psychiatry, 5, e498. doi:10.1038/tp.2014.143.CrossRefPubMedPubMedCentral

Wu, J., & Xie, X. (2006). Comparative sequence analysis reveals an intricate network among REST, CREB and miRNA in mediating neuronal gene expression. Genome Biology, 7(9), R85. doi:10.1186/gb-2006-7-9-r85.CrossRefPubMedPubMedCentral

Xu, B., Goulding, E. H., Zang, K., Cepoi, D., Cone, R. D., Jones, K. R., et al. (2003). Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nature Neuroscience, 6(7), 736–742. doi:10.1038/nn1073.CrossRefPubMedPubMedCentral

Yaffe, K., Krueger, K., Cummings, S. R., Blackwell, T., Henderson, V. W., Sarkar, S., et al. (2005). Effect of raloxifene on prevention of dementia and cognitive impairment in older women: The Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. American Journal of Psychiatry, 162(4), 683–690. doi:10.1176/appi.ajp.162.4.683.CrossRefPubMed

Yamashita, T., Tucker, K. L., & Barde, Y. A. (1999). Neurotrophin binding to the p75 receptor modulates Rho activity and axonal outgrowth. Neuron, 24(3), 585–593.CrossRefPubMed

Yang, G., Song, Y., Zhou, X., Deng, Y., Liu, T., Weng, G., et al. (2015). DNA methyltransferase 3, a target of microRNA-29c, contributes to neuronal proliferation by regulating the expression of brain-derived neurotrophic factor. Molecular Medicine Reports, 12(1), 1435–1442. doi:10.3892/mmr.2015.3531.PubMed

Yarrow, J. F., White, L. J., McCoy, S. C., & Borst, S. E. (2010). Training augments resistance exercise induced elevation of circulating brain derived neurotrophic factor (BDNF). Neuroscience Letters, 479(2), 161–165. doi:10.1016/j.neulet.2010.05.058.CrossRefPubMed

Yuan, X. B., Jin, M., Xu, X., Song, Y. Q., Wu, C. P., Poo, M. M., et al. (2003). Signalling and crosstalk of Rho GTPases in mediating axon guidance. Nature Cell Biology, 5(1), 38–45. doi:10.1038/ncb895.CrossRefPubMed

Zhao, Y.-N., Li, W.-F., Li, F., Zhang, Z., Dai, Y.-D., Xu, A.-L., et al. (2013). Resveratrol improves learning and memory in normally aged mice through microRNA-CREB pathway. Biochemical and Biophysical Research Communications, 435(4), 597–602. doi:10.1016/j.bbrc.2013.05.025.CrossRefPubMed

Zhao, X., Pan, F., Holt, C. M., Lewis, A. L., & Lu, J. R. (2009). Controlled delivery of antisense oligonucleotides: A brief review of current strategies. Expert Opinion on Drug Delivery, 6(7), 673–686. doi:10.1517/17425240902992894.CrossRefPubMed

Zuccato, C., & Cattaneo, E. (2007). Role of brain-derived neurotrophic factor in Huntington’s disease. Progress in Neurobiology, 81(5–6), 294–330. doi:10.1016/j.pneurobio.2007.01.003.CrossRefPubMed

Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., et al. (2001). Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. Science, 293(5529), 493–498. doi:10.1126/science.1059581.CrossRefPubMed

Titel: Targeting MicroRNAs Involved in the BDNF Signaling Impairment in Neurodegenerative Diseases
verfasst von: Hwa Jeong You
Jae Hyon Park
Helios Pareja-Galeano
Alejandro Lucia
Jae Il Shin
Publikationsdatum: 21.05.2016
Verlag: Springer US
Erschienen in: NeuroMolecular Medicine / Ausgabe 4/2016
Print ISSN: 1535-1084
Elektronische ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-016-8407-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Targeting MicroRNAs Involved in the BDNF Signaling Impairment in Neurodegenerative Diseases

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Potent Protection Against MPP+-Induced Neurotoxicity via Activating Transcription Factor MEF2D by a Novel Derivative of Naturally Occurring Danshensu/Tetramethylpyrazine

Metformin Protects Cells from Mutant Huntingtin Toxicity Through Activation of AMPK and Modulation of Mitochondrial Dynamics

The Diversity of Spine Synapses in Animals

Identification of miRNAs as Potential Biomarkers in Cerebrospinal Fluid from Amyotrophic Lateral Sclerosis Patients

A Novel Association of the Suppressor of Cytokine Signaling 1 (SOCS1) Gene Polymorphisms in Ischemic Stroke Patients

Plasma Amyloid Beta 1-42 and DNA Methylation Pattern Predict Accelerated Aging in Young Subjects with Down Syndrome

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie